Status:
COMPLETED
Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
Lead Sponsor:
University Hospital, Bonn
Conditions:
Age Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigat...
Eligibility Criteria
Inclusion
- Diagnosis of a pigment epithelial tear secondary to age-related macular degeneration
- Written informed consent
Exclusion
- Time of diagnosis more than 6 months before study recruitment
- Ocular surgery of the study eye within 1 month before study recruitment
- Extensive subretinal fibrosis or retinal atrophy of the study eye
- Significant opacification of optical media of the study eye
- Uncontrolled glaucoma of the study eye
- Active ocular inflammation of the study eye
- Best-corrected visual acuity of the contralateral eye below 20/200
- Concurrent ocular or systemic therapy with other vascular endothelial growth factor (VEGF)-inhibitory drugs
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01914159
Start Date
February 1 2013
End Date
March 1 2016
Last Update
August 15 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Bonn, Department of Ophthalmology
Bonn, Germany, 53127
2
University of München (LMU), Department of Ophthalmology
München, Germany, 80336
3
Universityof Münster, Department of Ophthalmology
Münster, Germany, 48149